Kim SJ - Search Results

1

EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.

Im YH, Kim HT, Lee C, Poulin D, Welford S, Sorensen PH, Denny CT, Kim SJ. Im YH, et al. Among authors: kim sj, kim ht. Cancer Res. 2000 Mar 15;60(6):1536-40. Cancer Res. 2000. PMID: 10749119

2

Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.

Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ, Kim SJ. Hahm KB, et al. Among authors: kim sj. Nat Genet. 1999 Oct;23(2):222-7. doi: 10.1038/13854. Nat Genet. 1999. PMID: 10508522

3

Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer.

Kang SH, Bang YJ, Im YH, Yang HK, Lee DA, Lee HY, Lee HS, Kim NK, Kim SJ. Kang SH, et al. Among authors: kim sj, kim nk. Oncogene. 1999 Dec 2;18(51):7280-6. doi: 10.1038/sj.onc.1203146. Oncogene. 1999. PMID: 10602482

4

Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis.

Kim SJ, Im YH, Markowitz SD, Bang YJ. Kim SJ, et al. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68. doi: 10.1016/s1359-6101(99)00039-8. Cytokine Growth Factor Rev. 2000. PMID: 10708963 Review.

5

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.

Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ. Lee BI, et al. Among authors: kim sj, kim ht, kim jw. Cancer Res. 2001 Feb 1;61(3):931-4. Cancer Res. 2001. PMID: 11221885

6

Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.

Im YH, Kim HT, Kim IY, Factor VM, Hahm KB, Anzano M, Jang JJ, Flanders K, Haines DC, Thorgeirsson SS, Sizeland A, Kim SJ. Im YH, et al. Among authors: kim iy, kim sj, kim ht. Cancer Res. 2001 Sep 15;61(18):6665-8. Cancer Res. 2001. PMID: 11559531

7

Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.

Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Won J, et al. Among authors: kim h, kim sj. Cancer Res. 1999 Mar 15;59(6):1273-7. Cancer Res. 1999. PMID: 10096559

8

Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.

Chang J, Lee C, Hahm KB, Yi Y, Choi SG, Kim SJ. Chang J, et al. Among authors: kim sj. Oncogene. 2000 Jan 6;19(1):151-4. doi: 10.1038/sj.onc.1203252. Oncogene. 2000. PMID: 10644990

9

Loss of TGF-beta signaling contributes to autoimmune pancreatitis.

Hahm KB, Im YH, Lee C, Parks WT, Bang YJ, Green JE, Kim SJ. Hahm KB, et al. Among authors: kim sj. J Clin Invest. 2000 Apr;105(8):1057-65. doi: 10.1172/JCI8337. J Clin Invest. 2000. PMID: 10772650 Free PMC article.

10

Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease.

Hahm KB, Im YH, Parks TW, Park SH, Markowitz S, Jung HY, Green J, Kim SJ. Hahm KB, et al. Among authors: kim sj. Gut. 2001 Aug;49(2):190-8. doi: 10.1136/gut.49.2.190. Gut. 2001. PMID: 11454793 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,261 results

Search Page

Filters